LDL Hypothesis Brings Out Skeptics, Supporters At FDA Panel
Agency told advisory committee weighing the IMPROVE-IT data not to debate the LDL-hypothesis; panelists did so anyway.
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker.
FDA’s complete response letter for the cardiovascular risk reduction claim for Zetia/Vytorin was expected, but what will this mean for sponsors of drugs with other mechanisms, like PCSK9?
Esperion says it is working with FDA to forge a new regulatory path for its cholesterol drug ETC-1002 in statin-intolerant patients – a population the agency has been very cautious about in the past.